Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Comment by bluemoons20on Mar 19, 2024 10:52am
85 Views
Post# 35940532

RE:RE:Only hope is YOFOTO. or Second LOI by others.....

RE:RE:Only hope is YOFOTO. or Second LOI by others.....Whole  deal  is  very one sided.
Interesting they  mention  the  number 160 million  and limit  shareholder payout to 8%  or  $2  per share.  Do they have someone  ready to buy for that  price??  (or more??)

Reallt  today  that is not a lot of money!!

Also  , why limit  shareholders to only  8%  rather than  say  50%  -  Ifreplicel was doing its job to  benefit all shareholders  it could have sold the assets  for everyone's benefit.   Also  the total  shareholder stake is capped @  $2  per share.  Even if it comes in it is  paid as  income or a dividend  which would get taxed at a higher rate that  capital gains.

If they are looking to  sell the assets  now  , they could have put out feelers  right after the  arbitration  and not wasted time  figuring out  how to  enrich  the largest shareholder.   Seems like everyone  just sat around and collected a big salary  while  shiedo  did some tests  rather than try to make the company  work!!

Maybe  some other large shareholder  or  other party will come up with a better takeover  offer??

We can only  hope.

If they were being fair, they should  buy out  the  outside shareholders for  the  $2  per share  right now  and then get on with the  deal.  Maybe someone  would prefer that  to  what we have  now??

GLTA
<< Previous
Bullboard Posts
Next >>